Abstract

Agilent Technologies will release its fiscal third-quarter 2026 results on August 26, 2026, Post-Mkt; consensus indicates mid–single-digit adjusted EPS growth and a low–double-digit revenue increase, with investors watching services mix, diagnostics catalysts, and the sustainability of the company’s margin profile.

Market Forecast

Consensus for this quarter points to revenue of 1.84 billion US dollars, adjusted EPS of 1.49, and EBIT of 484.26 million US dollars, implying year-over-year increases of 10.57%, 8.80%, and 12.02%, respectively; there is no explicit consensus figure for gross margin or net margin for the quarter, and most watchers infer a stable margin profile given the services mix. Based on the last reported quarter’s segment composition, Agilent CrossLab Services stood out as the largest revenue contributor at 759.00 million US dollars, and the recurring nature of service and software contracts is expected to underpin top-line resilience and gross margin steadiness. Within the product and diagnostics mix, the Life Sciences and Diagnostics Market segment generated 732.00 million US dollars last quarter and is viewed as a key growth avenue supported by recent companion-diagnostic approvals and portfolio additions; alongside the company-level forecast revenue growth of 10.57% year over year, this segment is expected to benefit from an improved test menu and integration momentum.

Last Quarter Review

In the prior quarter, Agilent Technologies delivered revenue of 1.84 billion US dollars, a gross profit margin of 54.11%, GAAP net profit attributable to shareholders of 339.00 million US dollars, a net profit margin of 18.47%, and adjusted EPS of 1.49; year over year, revenue rose 10.01% and adjusted EPS increased 13.74%. Net profit grew 11.15% sequentially, reflecting disciplined operating expense control and favorable business mix. By segment, Agilent CrossLab Services contributed 759.00 million US dollars, the Life Sciences and Diagnostics Market contributed 732.00 million US dollars, and the Applied Markets business delivered 344.00 million US dollars, a combination that supported the company’s 10.01% year-over-year revenue growth in the quarter.

Current Quarter Outlook

Agilent CrossLab Services: Margin anchor and recurring growth

CrossLab Services is the company’s largest revenue line and the most consistent margin anchor in the model. With 759.00 million US dollars posted last quarter, this portfolio of service contracts, consumables, compliance services, and software provides visibility into quarterly cash generation and helps smooth the instrument cycle. Its recurring nature typically requires less discounting than instrument sales and benefits from a growing installed base of systems, which tends to lift attach rates over time. In the current quarter, consensus expects company-level revenue to grow 10.57% year over year, and a meaningful portion of that trajectory is tied to sustained service demand from regulated labs and enterprise accounts renewing multi-year agreements. Management has also been emphasizing software-enabled workflows and digital tools that improve uptime and compliance. The recently promoted OpenLab software workflow offerings and the new OpenLab Sync product suite are designed to increase customer stickiness and expand subscription-type revenue, which can preserve gross margin even as hardware mix fluctuates. From a working-capital lens, services require limited incremental inventory and can convert to cash rapidly, offering support for free-cash-flow cadence post-quarter end. For equity holders focusing on near-term earnings, the CrossLab contribution matters because it tends to hold gross profit per dollar of revenue steadier than hardware, making it a key factor behind the consensus expectation of stable profitability in the absence of explicit margin guidance.

Life Sciences and Diagnostics: Regulatory catalysts and early synergy from Biocare

The Life Sciences and Diagnostics Market segment delivered 732.00 million US dollars last quarter and sits at the center of several recent portfolio catalysts. In the past six months, the company reported new regulatory clearances for its PD-L1 companion diagnostics, including the PD-L1 IHC 28-8 pharmDx in the United States and an expansion of the PD-L1 IHC 22C3 pharmDx test in the European Union for specific cancer types. These clearances broaden the utility of the company’s assays in clinical decision-making and support test adoption within hospital and reference lab settings. Furthermore, the completion of the Biocare Medical acquisition adds complementary reagents and antibodies, deepening the company’s diagnostics menu and potentially increasing average revenue per installed staining system. Integration benefits in the near term are likely to show up as expanded placement opportunities and cross-selling within existing pathology accounts. As the quarter progresses, investors will monitor early revenue synergy markers such as incremental orders for newly approved indications, larger pull-through of reagents per site, and the pace of contracts signed with oncology centers adopting the updated test menu. While the absolute revenue split between clinical and research-driven demand is not guided for the quarter, the presence of tangible regulatory milestones supports the notion that diagnostics is positioned to contribute disproportionately to incremental growth versus the corporate average. For profitability, diagnostics consumables typically carry favorable gross margins once volume is established, which can complement the services contribution to overall margin stability.

Stock-price swing factors this quarter

Short-term equity performance will likely hinge on how reported revenue and adjusted EPS compare with the 1.84 billion US dollars and 1.49 benchmarks embedded in consensus, as well as management’s tone on the sustainability of double-digit top-line growth. Any update on order patterns for high-performance liquid chromatography, mass spectrometry, and spectroscopy systems can shift expectations for second-half instrument shipments, which in turn influences revenue phasing and operating leverage. On the margin line, investors will parse gross margin drivers—services mix, consumables pull-through, and diagnostic reagent volume—given the prior quarter’s 54.11% result and the absence of explicit margin guidance for this print. Opex discipline remains another focal point; holding spending growth below revenue growth would help translate the 10.57% expected top-line increase into mid– to high–single-digit adjusted EPS growth. Recent product introductions in digital lab execution and informatics provide an incremental software layer that can enhance lifetime value per customer; management commentary around early adoption and pricing should inform how much of that uplift is already in the run-rate. M&A integration updates following the Biocare Medical transaction are also relevant; concrete examples of co-selling wins or expanded assay placements could lead to positive estimate revisions for diagnostics. Finally, capital deployment remains supportive of per-share metrics; repurchases disclosed earlier in the year and the ongoing dividend cadence offer a backdrop for adjusted EPS maintenance even if mix swings within hardware categories.

Analyst Opinions

Analyst sentiment skews clearly bullish in the past six months, with at least six Buy/Overweight/Outperform ratings versus zero Sell/Underperform ratings among the opinions observed, a 6:0 bullish-to-bearish ratio excluding a single Hold. Notably, Morgan Stanley maintained an Overweight rating and raised its price target to 175 US dollars in August, citing improving growth visibility and confidence in multi-quarter earnings recovery as services and diagnostics scale. Goldman Sachs reaffirmed a Buy rating with a 155 US dollars target, emphasizing the durability of the company’s recurring revenue and the earnings contribution from operational execution following the prior quarter’s better-than-expected results. Bernstein kept a Buy at 155 US dollars, pointing to constructive demand indications and the benefits of portfolio breadth that support cross-selling and customer retention. Barclays maintained a Buy with a 145 US dollars target, highlighting the potential upside from new product workflows and improved order conversion. BofA Global Research upgraded the shares to Buy after the May results day, attributing the move to a combination of outperformance in the quarter and a higher full-year profit outlook. Baird reiterated Outperform and nudged its target to 160 US dollars, underscoring progress in execution and the resilience of cash-generation drivers.

The common threads across these bullish perspectives are consistent with the setup for this earnings event. First, analysts broadly expect a favorable revenue mix with a larger services and consumables contribution, which historically helps sustain gross margins and reduce earnings volatility. This dovetails with the 1.84 billion US dollars revenue and 1.49 adjusted EPS benchmarks, where upside would most likely come from higher services attach rates and stronger reagent pull-through in diagnostics. Second, several institutions are incorporating the impact of recent PD-L1 test approvals and the completion of the Biocare Medical acquisition into their near-term models. These items provide tangible catalysts for the clinical diagnostics portfolio, with potential for incremental placements and assay volume that can show up in revenue as the quarter progresses, even if the majority of full synergy realization is a multi-quarter theme. Third, execution in expense management remains a focus, and the prior quarter’s 11.15% sequential increase in net profit suggests the company is translating growth into bottom-line results; analysts expect management to keep operating spending in check relative to revenue growth.

Institutional views also reflect confidence that the company’s guidance trajectory is improving following the late-May results day, when full-year profit guidance was raised and the stock responded positively. Since then, incremental data points—product announcements, regulatory clearances, and a completed tuck-in acquisition—have provided analysts with additional reasons to stay constructive into the print. While there are no explicit margin forecasts from the consensus set we reviewed, commentary from bullish houses implies that mix and pricing should be sufficient for the company to deliver stable profitability accompanied by the forecasted 8.80% year-over-year growth in adjusted EPS. Should the company’s reported numbers at least meet the revenue and EPS thresholds while showing continued momentum in services and diagnostics, the majority of analysts expect positive estimate revisions for the back half. In that scenario, current price targets in the 145–175 US dollars range appear anchored in expectations for mid–single-digit to high–single-digit EPS growth on top of low–double-digit revenue growth, a profile they view as balanced for risk and reward. Overall, the preponderance of Buy and Overweight ratings signals that institutions anticipate an in-line to better-than-expected print, driven by services resilience, diagnostics catalysts, and disciplined cost management this quarter.